Prognosis and biological characteristics of ER-low metastatic breast cancer: results from a multicenter cohort and the TONIC trial. Abstract. Purpose: To assess prognosis of ER-low expression and its dynamics in HER2- metastatic breast cancer (BC) and to compare sensitivity to nivolumab between ER-low and triple-negative (TN) BC. ...

🎯 Clinical impact: ER-low BC should be managed more like TNBC, with inclusion in immunotherapy & ADC trials. Re-biopsy at relapse is crucial to detect phenotype switch.

#BreastCancer #ERlow #TNBC #Immunotherapy #Medicalwatch
aacrjournals.org/clincancerre...